CD274 and gastric neoplasm: Several clinical trials, for example, KEYNOTE-012 and KEYNOTE-059, proved the efficacy of immune checkpoint inhibitors, targeting PD-L1, such as pembrolizumab, for the treatment of MSI-high gastric tumours overexpressing PD-L1 [13,14].